Irreversible corneal decompensation in patients treated with topical dorzolamide.
about
Cornea and ocular surface disease: application of cutting-edge optometric researchIdentification and cloning of the Na/HCO(3-) cotransporter (NBC) in human corneal endotheliumManaging adverse effects of glaucoma medicationsEffect of topical dorzolamide on rabbit central corneal thicknessPost-penetrating keratoplasty glaucomaCarbonic anhydrase inhibitors. metal complexes of 5-(2-chlorophenyl)-1,3,4-thiadiazole-2-sulfonamide with topical intraocular pressure lowering properties: the influence of metal ions upon the pharmacological activity.Management of patients with combined glaucoma and corneal transplant surgery.Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride.CD147 required for corneal endothelial lactate transport.Pharmaceutical management of the childhood glaucomas.Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells.Knockdown of NBCe1 in vivo compromises the corneal endothelial pump.Effects of argon laser iridotomy on the corneal endothelium of pigmented rabbit eyes.Short- and long-term safety of glaucoma drugs.Corneal transplantation and glaucoma.Allergic contact dermatitis caused by dorzolamide eyedrops.Periorbital dermatitis as a side effect of topical dorzolamide.Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells.Comparison of Cytotoxic Effects on Rabbit Corneal Endothelium between Preservative-free and Preservative-containing Dorzolamide/timololChanges in Corneal Endothelial Cell after Ahmed Glaucoma Valve Implantation and Trabeculectomy: 1-Year Follow-up.Topical treatment of glaucoma: established and emerging pharmacology.Role of carbonic anhydrase IV in corneal endothelial HCO3- transport.Brinzolamide.Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension.Emerging drugs for ocular hypertension.Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue.Comparative cross-sectional analysis of the effects of topical antiglaucoma drugs on the ocular surface.Antiglaucoma carbonic anhydrase inhibitors: a patent review.Present and New Treatment Strategies in the Management of Glaucoma.The effect of prophylactic topical carbonic anhydrase inhibitors in canine primary closed-angle glaucoma.Glaucoma and corneal transplant procedures.Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%).Brinzolamide induced reversible corneal decompensation.First aid for complications of infectious keratitis.Carbonic anhydrase inhibitors: synthesis and inhibition against isozymes I, II and IV of topically acting antiglaucoma sulfonamides incorporating cis-5-norbornene-endo-3-carboxy-2-carboxamido moieties.Ocular surface - a complex and vulnerable adoptive environment for topical glaucoma treatment.Glaucoma-Intraocular Pressure Reduction.
P2860
Q27010492-D82824BA-D21C-4CD5-BF79-EBAE6C59FB3AQ28156138-7D105428-22F4-48E5-88EF-667F5D946445Q28240902-07949530-EC41-4AE8-87CE-D0FBA4231C04Q29028120-EAE21167-1E6D-48DC-A8D6-BD0262F6E829Q30491374-9B675C73-8B2A-4C59-944F-4E785B879382Q31427008-3FF2A628-E117-48AA-84BB-5A9E08DA5991Q33400737-AD2E12B0-2823-4A86-9347-C5587B69DFC8Q33573405-E8E752C7-BA6D-4E83-9338-797BEE74F900Q33975123-42DD7104-CC41-43E2-BC06-1D951F059E58Q34182084-D3FB3B56-0C24-4D74-852E-25CE2CE97A0BQ34245277-D53F157F-6EA0-4BA4-8398-B2B6A6323D27Q34735219-F9FF479A-B0FE-4208-A3B0-240D9F5401EEQ35087992-2628632F-4BC0-4538-86C1-13DD10DBFC80Q35194520-2D65925B-A0BE-4ACB-BE66-05B29F4E2281Q35344262-C0514A98-92F7-4D3C-A70E-8CE1D5909F79Q35407897-4D4F9F85-2C29-49F4-B5D3-799E32315C68Q35589658-E0E98283-E04E-47C9-992F-28A6E3D8042DQ36069143-9EDEB95E-3312-4387-8BC8-28742B99D468Q36127299-85195843-1AD3-46CB-8D39-689CD11801DCQ36225922-67A95AD4-69F4-4D81-B03F-761C3BE84AAFQ36365495-0BC2A58A-69CB-4280-9040-2174E40B7B7EQ36580724-001FFB5D-5326-4122-BDA0-676809A12C32Q37099034-FC18C806-195F-41CB-943B-4BBE1F044149Q37577462-DCEA01ED-10C5-4C1B-AA67-F942D49EE139Q37847182-C256ABF0-C694-4594-8CDC-6DCC8A4C0AA4Q37856242-879E8A06-6EA9-4698-98C2-62A39A1E29D7Q38096951-5FFD7F92-4D5C-4C1A-8412-67DB011614E8Q38102786-BE654C99-FB1B-400F-8B1E-C2E2E0FC934CQ38526185-64B66C22-C5AD-409E-8004-67E51978F08EQ40580368-BCE6C658-010A-4DDE-AF90-BEB8B93FCA7DQ40796983-8E1096DE-1260-4531-A0D7-BE5888B447F9Q41352665-8CD7E451-A089-47A2-A505-3BB87A80C212Q43007280-E15F45CF-CA1E-447F-A6F4-D9EF28A9FFBDQ43187223-F759A27B-5A8E-4834-ADA9-1F8C3AD035ACQ43600738-6A8550EC-2469-468E-A085-D6A229C8D0E8Q47170651-92A17A95-8AD8-49EB-887C-7E044FEBD6F3Q53555670-C6E64BF8-A950-49C5-AF7C-E149B7ABADEF
P2860
Irreversible corneal decompensation in patients treated with topical dorzolamide.
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Irreversible corneal decompensation in patients treated with topical dorzolamide.
@ast
Irreversible corneal decompensation in patients treated with topical dorzolamide.
@en
type
label
Irreversible corneal decompensation in patients treated with topical dorzolamide.
@ast
Irreversible corneal decompensation in patients treated with topical dorzolamide.
@en
prefLabel
Irreversible corneal decompensation in patients treated with topical dorzolamide.
@ast
Irreversible corneal decompensation in patients treated with topical dorzolamide.
@en
P2093
P1476
Irreversible corneal decompensation in patients treated with topical dorzolamide.
@en
P2093
Epstein RJ
Fraunfelder FT
Maguire LJ
Morrison JC
Verdier DV
P304
P356
10.1016/S0002-9394(98)00438-3
P407
P577
1999-04-01T00:00:00Z